Mind Cure brings in an expert in fintech to be its new CTO.
Mind Cure brings in an expert in fintech to be its new CTO.
Field Trip's new strategic partnership will facilitate bringing its ketamine-assisted psychotherapy for PTSD to military veterans.
Primo Nutraceuticals is commencing preliminary psychedelics research in a partnership with Mecan Biotech.
Numinus rolls out the list of Advisors on its psychedelics Advisory Council
The newest psychedelics company plans to focus on both ketamine- and psilocybin-assisted psychedelics R&D.
Mind Cure adds an expert in neuroscience and nutrition to its Advisory Board.
MindMed announces a CAD$25 million bought-deal financing at CAD$1.05 per unit.
Field Trip has appointed a leader in holistic and integrative medicine to its Medical Advisory Board.
Numinus commences psilocybin cultivation as part of its "ecosystem approach" to psychedelic drug therapy.
This is Mind Cure's third high-profile addition to its Scientific Advisory Board in the last week.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now